Objectives: Equid herpesvirus (EHV) type 1 is an enveloped DNA virus classified within the family Alphaherpesviridae in the order Herpesvirales [1]. It is genetically and antigenically similar to EHV-4. Infection with equid herpesvirus 1 (EHV-1) may be asymptomatic, or may result in respiratory disease, abortion, neonatal death, or neurological disease referred to as equine herpesvirus myeloencephalopathy (EHM) [2, 3]. Recently, an amino acid substitution from asparagine (N) to aspartic acid (D) at amino acid position 752 of the viral DNA polymerase has been associated with increased neurovirulence [4]. The aim of this study was to estimate the prevalence of EHV-1 infection, including differentiation between D752 and N752 genotypes, within a selected population of New Zealand horses. The second aim was to determine the predictive value of serology for detection of latently infected horses.
Methods: Retropharyngeal lymph nodes (RLN) and trigeminal ganglia (TG) were dissected from 52 horses at slaughter and tested for the presence of EHV-1 DNA using magnetic bead, sequence-capture enrichment followed by nested PCR. Sera were tested for EHV-1 antibody using type-specific glycoprotein G ELISA.
Results and Conclusions: Overall, 17/52 horses tested positive for EHV-1 DNA. All but one positive PCR results were obtained from RLN samples. Fifteen of the EHV-1 positive horses harboured EHV-1 with N752 genotype, one of which was additionally infected with the D752 genotypes of the virus [5]. Our data comprise the first detection of EHV-1 with D752 genotype in New Zealand and suggest that this variant of EHV-1 had been present in New Zealand for at least two years before the first reported outbreak of EHM. All sampled horses tested positive for EHV-4 antibody, and 11/52 tested positive for EHV-1 antibody. The strength of agreement between results of EHV-1 PCR and EHV-1 serology was “fair” (Kappa 0.259, 95% CI: −0.022–0.539).